ongoing

The TheRAPy is a pragmatic, multicentre, cluster-randomized, crossover trial that will determine the feasibility of studying whether an institutional policy of routine use of autologous priming reduces red blood cell transfusion up to 72 hours after cardiac surgery when compared with a policy of crystalloid priming.

Learn More about TheRAPY
Study Type

Pragmatic Clinical Trial

Study Design

Multicentre, cluster-randomized, crossover trial

NO. of Countries

1

NO. of Sites

20

NO. of Participants

16,800

Study Period

2026-2030

Sponsor

PHRI

Canadian Institutes of Health Research (CIHR)

Hamilton Academic Health Sciences Organization (HAHSO)

Accelerating Clinical Trials (ACT) Consortium

Back To Top